Page 98 - GTM-3-4

Global Translational Medicine Blood parameters for SCLC and AC relapse prognosis

doi: 10.1007/s00432-019-03079-8 doi: 10.1378/chest.10-3279

29. Lu J, Wang Y, Yan M, et al. High serum haptoglobin level 32. Berghmans T, Paesmans M, Sculier JP. Prognostic factors
is associated with tumor progression and predicts poor in stage III non-small cell lung cancer: A review of
prognosis in non-small cell lung cancer. Oncotarget. conventional, metabolic and new biological variables. Ther
2016;7(27):41758-41766. Adv Med Oncol. 2011;3(3):127-138.
doi: 10.18632/oncotarget.9676 doi: 10.1177/1758834011401951
30. Burki TK. Late detection of lung cancer. Lancet Oncol. 33. Yun JK, Lee GD, Choi S, et al. Various recurrence dynamics
2014;15(13):e590. for non-small cell lung cancer depending on pathological
stage and histology after surgical resection. Transl Lung
doi: 10.1016/S1470-2045(14)70371-7 Cancer Res. 2022;11(7):1327-1336.
31. Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K. doi: 10.21037/tlcr-21-1028
Risk factors for tumor recurrence in patients with early-stage
(stage I and II) non-small cell lung cancer: Patient selection 34. Hosmer DW, Lemeshow S, Sturdivant RX. Applied Logistic
rd
criteria for adjuvant chemotherapy according to the seventh Regression. 3 ed. Hoboken, NJ: John Wiley & Sons; 2013.
edition TNM classification. Chest. 2011;140(6):1494-1502. doi: 10.1002/9781118548387

Volume 3 Issue 4 (2024) 14 doi: 10.36922/gtm.4865